2’,7’-二氯-5(6)-羧基荧光素的合成及其荧光性能研究

以偏苯三酸酐、4-氯间苯二酚为原料,在ZnCl2催化下反应得到2',7'-二氯-5(6)-羧基荧光素混合物,并用柱色谱进行异构体分离.对取代基团对其荧光性能影响的研究发现,顶环上引入氯使其最大荧光激发波长和荧光发射波长发生红移,荧光强度有所增加;底环上引入羧基,其Stokes位移和荧光量子产率略有降低,但该活性基团的引入将更有利于对生物体进行检测.由此表明,2',7'-二氯-5(6)-羧基荧光素有望用于荧光探针.     

5(6)-羧基荧光素标记2''-脱氧尿苷的合成

以5-碘-2'-脱氧尿嘧啶为起始原料,5(6)-羧基荧光素为荧光标记物,经6步反应合成了5(6)-羧基荧光素标记的2'-脱氧尿苷,并利用高效液相色谱(HPLC),1H NMR和13C NMR对目标化合物的纯度和结构进行了表征.     

5(6)-羧基荧光素标记2′-脱氧尿苷的合成

以5-碘-2'-脱氧尿嘧啶为起始原料, 5(6)-羧基荧光素为荧光标记物, 经6步反应合成了5(6)-羧基荧光素标记的2′-脱氧尿苷, 并利用高效液相色谱(HPLC), ¹H NMR和¹³C NMR对目标化合物的纯度和结构进行了表征.     

6-取代氨基-2-烷硫基腺苷化合物的合成及抗血小板凝聚活性

以鸟苷(1)为原料, 经过糖环保护得到2',3',5'-三-O-乙酰基鸟嘌呤核苷(2), 化合物2与三氯氧磷反应得到2-氨基-6-氯-9-(2',3',5'-三-O-乙酰基-β-D-呋喃核糖基)嘌呤(3), 化合物3经重氮化后再与二烷基二硫醚反应得到2-烷硫基-6-氯-9-(2',3',5'-三-O-乙酰基-β-D-呋喃核糖基)嘌呤(4a~4d), 化合物4a~4d与胺进行亲核取代反应后, 脱去糖环保护得到12个新型的6-取代氨基-2-烷硫基腺苷化合物(5a~5l). 采用¹H NMR, ¹³C NMR, IR和高分辨质谱(HRMS)对目标化合物的结构进行了确证, 并对所有化合物进行了体外抗血小板聚集活性测试. 结果表明, 当测试浓度为10 μmol/L时, 化合物5a~5l仍具有一定的抗凝活性, 其中, 6-(3-苯基丙基)氨基-2-丙硫基腺苷(5d)活性最为显著, 抑制率可达90.2%.     

2,6-二甲基-3,5-二氯-4-吡啶酚糖苷的合成

在相转移催化条件下, 使 a-D-乙酰基化溴代的葡萄糖、半乳糖、葡萄糖醛酸甲酯1a, 1b, 1c分别与2,6-二甲基-3,5-二氯-4-吡啶酚(俗称氯吡醇, 氯羟吡啶)作用, 合成了氯吡醇的糖苷: 1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4,6-四-O-乙酰基-β-D-葡萄吡喃糖苷(2a), 1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4,6-四-O-乙酰基β-D-半乳吡喃糖苷(2b), 1-O-(2'6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4-三-O-乙酰基-β-D-葡萄吡喃糖醛酸甲酯(2c)。2a, 2b, 2c分别在甲醇中氨解, 相应得到: 1-O-(2', 6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-葡萄吡喃糖苷(3a), 1-O(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-半乳吡喃糖苷(3b),1-O-(2', 6'-二甲基-3',5'-二氯-(4'-吡啶基)-β-D-葡萄吡喃糖醛酸酰胺(3c)。2c用CH~3ONa/CH~3OH处理, 得到1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-葡萄吡喃糖醛酸甲酯(3d)。     

酰氨基硫脲及相关杂环衍生物的研究XXIX: 2-(3'-溴苯胺基)-5-[5'-氨基-1'-(4"-氯苯基)-1',2',3'-三唑-4'-基]-1,3,4-噻二唑的晶体结构

经1-[5'-氨基-1'-(4"-氯苯基)-1',2',3'-三唑-4'-甲酰基]-4-(3'-溴苯基)-3-氨基硫脲在浓硫酸作用下制得2-(3'-溴苯胺基)-5-[5'-氨基-1'-(4"-氯苯基)-1',2',3'-三唑-4'-基]-1,3,4-噻二唑化合物。该化合物的晶体结构经X射线衍射分析确定, 化合物属三斜晶系, P1空间群, a=1.1784(2), b=1.4455(2),c=1.1353(1)nm; α=100.68(1), β=109.50(1), γ=79.89(1)°; V=1.7779nm^3; 分子式C~1~6H~1~1BrClN~7S, Mr=448.75; Dc=1.673g/cm^3, Z=4,μ=58.16cm^-^1, 最终偏离因子R=0.084, Rw=0.086。分析化合物的键长, 键角数据表明, 该分子具有离域π键结构。     

合成卡培他滨的新方法

1',2',3'-0-三乙酰基核糖与硅醚化的5-氟胞嘧啶缩合制备了2',3'-0-二乙酰基-5'-脱氧-5-氟胞苷(2);2再与氯甲酸正戊酯反应得到2',3'-0-二乙酰基-5'-脱氧-5-氟-N4-[(戊氧基)羰基]胞苷(3);3经皂化合成了卡培他滨(总产率53%),其结构经1H NMR和元素分析表征.     

酰氨基硫脲及相关杂环衍生物的研究XXIX: 2-(3'-溴苯胺基)-5-[5'-氨基-1'-(4"-氯苯基)-1',2',3'-三唑-4'-基]-1,3,4-噻二唑的晶体结构

经1-[5'-氨基-1'-(4"-氯苯基)-1',2',3'-三唑-4'-甲酰基]-4-(3'-溴苯基)-3-氨基硫脲在浓硫酸作用下制得2-(3'-溴苯胺基)-5-[5'-氨基-1'-(4"-氯苯基)-1',2',3'-三唑-4'-基]-1,3,4-噻二唑化合物。该化合物的晶体结构经X射线衍射分析确定, 化合物属三斜晶系, P1空间群, a=1.1784(2), b=1.4455(2),c=1.1353(1)nm; α=100.68(1), β=109.50(1), γ=79.89(1)°; V=1.7779nm^3; 分子式C~1~6H~1~1BrClN~7S, Mr=448.75; Dc=1.673g/cm^3, Z=4,μ=58.16cm^-^1, 最终偏离因子R=0.084, Rw=0.086。分析化合物的键长, 键角数据表明, 该分子具有离域π键结构。     

N~6,N~6-二(叔丁氧羰基)-2',3'-O-异丙叉腺苷的合成

以腺苷(2)为原料,经丙酮叉保护2',3'-位羟基得2',3'-O-异丙叉腺苷(3);3经叔丁基二甲硅氯保护5'-羟基得5'-O-叔丁二甲基硅基-2',3'-O-异丙叉腺苷(4);4经二碳酸二叔丁酯保护氨基得到N~6,N~6-二(叔丁氧羰基)-2',3'-O-异丙叉基-5'-O-叔丁二甲基硅基腺苷(5);5用四丁基氟化铵脱去叔丁二甲基硅基合成了新化合物N`6,N~6-二(叔丁氧羰基)-2',3'-O-异丙叉腺苷,总收率54.3%,其结构经~1H NMR,~(13)C NMR,IR和HR-MS表征.     

新型蒎烷基吡唑酰胺类衍生物的合成及其生物活性研究

以诺蒎酮为原料,合成了新型蒎烷基吡唑酰胺类衍生物,并对其生物活性进行了研究.诺蒎酮与芳香醛进行缩合反应,得到中间体3-芳亚甲基诺蒎酮2a~2g,2a~2g与水合肼经环化、脱氢芳构化反应,得到新型蒎烷基吡唑类化合物3a~3g;以N,N-二甲基甲酰胺为溶剂,3a~3g与2-氯乙酰胺在碱催化作用下,合成了7种吡唑酰胺类化合物4a~4g.其结构经~1H NMR,~(13)C NMR,IR,和HRMS表征.通过X射线衍射分析测定了化合物2-(6',6'-二甲基-3'-(4'-甲氧基苯基)-4',5',6',7'-四氢-5',7'-桥亚甲基-吲唑-1'-基)乙酰胺(4d)的晶体结构.探讨了化合物3a~3g和4a~4g的抑菌活性和对蚜虫的杀虫活性.实验结果表明,2-(6',6'-二甲基-3'-(4'-氟苯基)-4',5',6',7'-四氢-5',7'-桥亚甲基-吲唑-1'-基)乙酰胺(4g)既具有较好的抑菌效果,同时对紫薇蚜虫也表现出较好的杀虫活性.     

2-芳胺基-5-[5'-氨基-1'-(4"-氯苯基)-1',2',3'-三唑-4'-基]-1,3,4-噻二唑的合成

1-[5'-氨基-1'-(4"-氯苯基)-1,2,3-三唑-4'-甲酰基]-4-芳基-3-氨基硫脲在浓硫酸催化下环化得到2-芳胺基-5-[5'-氨基-1'-(4"-氯苯基)-1',2',3',-三唑-4'-基]-1,3,4-噻二唑2a-i, 依此法合成了九个标题化合物, 收率为30-74%。化合物2i的结构用X-光衍射单晶分析确证。     

2-芳胺基-5-[5′-氨基-1′-(4″-氯苯基)-1′,2′,3′-三唑-4′-基]-1,3,4-噻二唑的合成~≠

1-[5’-氨基-1’-(4”-氯苯基)-1,2,3-三唑-4’-甲酰基]-4-芳基-3-氨基硫脲在浓硫酸催化下环化得到2-芳胺基-5-[5’-氨基-1’-(4”-氯苯基)-1’,2’,3’,-三唑-4’-基]-1,3,4-噻二唑2a～i,依次法合成了九个标题化合物,收率为30～74％。化合物2i的结构用X-光衍射单晶分析确证。     

4',5'-Dichloro-2',7'-dimethoxy-5(6)-carboxyfluorescein (JOE): synthesis and spectral properties of oligonucleotide conjugates

A convenient procedure for the preparation of the fluorescent dye 4',5'-dichloro-2',7'-dimethoxy-5(6)-carboxyfluorescein (JOE) is reported; the overall yield achieved starting from isovanillin is 10 times higher (40% vs 4%) compared to the known procedure. Isomers (5- and 6-) are easily chromatographically separable as pentafluorophenyl esters of 3',6'-O-bis(cyclohexylcarbonyl) derivatives. Four non-nucleoside JOE phosphoramidites based on 5- and 6-isomers and flexible 6-aminohexanol (AH) or rigid 4-trans-aminocyclohexanol (ACH) linkers have been prepared and used for oligonucleotide labeling. Spectral and photophysical properties of 5'-JOE-modified oligonucleotides have been studied. Fluorescence quantum yield of the dye correlates with the nature of the linker (rigid vs flexible) and with the presence of dG nucleosides in close proximity to a JOE residue.     

Synthesis and anti-diabetic activity evaluation of phosphonates containing thiazolidinedione moiety

Abstract

A sequence of substituted phosphonates containing the thiazolidinedione moiety was synthesized with good yields. The structures of all the synthesized compounds were confirmed by NMR (³¹P, ¹H and ¹³C) and IR spectroscopy, mass spectrometry and C, H, N elemental analyses. In silico molecular docking study was also carried out to evaluate their interaction and binding modes on ligands against human PPAR γ protein for their anti-diabetic activity. From the docking results, it was determined that the compounds (Z)-dimethyl 5-(3-nitrobenzylidene)?2,4-dioxothiazolidin-3-ylphosphonate (7a), (Z)-dimethyl 5-(3-chloro-4-fluorobenzylidene)?2,4-dioxothiazolidin-3-ylphosphonate (7f), (Z)-dimethyl 5-(2,4-dichlorobenzylidene)?2,4-dioxothiazolidin-3-ylphosphonate (7e) and (Z)-dimethyl 5-((5-methoxypyridin-2-yl)methylene)?2,4-dioxothiazolidin-3-ylphosphonate (7j) have shown better binding energies (?7.8, ?7.6, ?7.5 and ?7.6 Kcal/mol) with the target gene, PPAR γ than the reference drug, Rosiglitazone (?7.4 Kcal/mol). In vitro anti-diabetic activity of the title compounds was also screened by standard α-amylase inhibition assay. Some of the tested compounds proved to possess promising activity when compared with the reference drug.     

1,2,4-三嗪类化合物的研究 VIII: 3-甲硫基-5-羟基-1,2,4-三嗪-6-羧酸乙酯和N^2-[5'-(3'-甲硫基-6'-乙氧羰基)-1',2',4'-三嗪基]-3-甲硫基-5-氧代-1,2,4-三嗪-6-羧酸乙酯的氧化及其取代反应

本文报道3-甲硫基-5-羟基-1,2,4-三嗪-6-羧酸乙酯(4)及N^2-[5'-(3'-甲硫基-6'-乙氧羰基)-1',2',4'-三嗪基]-3-甲硫基-5-氧代-1,2,4-三嗪-6-羧酸乙酯(8)分子内,甲硫基的氧化及其就地与取代芳胺进行亲核取代反应.3-甲砜基和N^2-[5'-(3'-甲硫基-6'-乙氧羰基)-1',2',4'-三嗪基]作为离去基,其离去能力相近.     

Synthesis of 4-thiouridine, 6-thioinosine, and 6-thioguanosine 3',5'-O-bisphosphates as donor molecules for RNA ligation and their application to the synthesis of photoactivatable TMG-capped U1 snRNA fragments

4-Thiouridine, 6-thioguanosine, and 6-thioinosine 3',5'-bisphosphates (9, 20, and 28) were synthesized in good yields by considerably improved methods. In the former two compounds, uridine and 2-N-phenylacetylguanosine were converted via transient O-trimethylsilylation to the corresponding 4- and 6-O-benzenesulfonyl intermediates (2 and 13), which, in turn, were allowed to react with 2-cyanoethanethiol in the presence of N-methylpyrrolidine to give 4-thiouridine (3) and 2-N-phenylacetyl-6-thioguanosine derivatives (14), respectively. In situ dimethoxytritylation of these thionucleoside derivatives gave the 5'-masked products 4 and 15 in high overall yields from 1 and 11. 6-S-(2-Cyanoethyl)-5'-O-(4,4'-dimethoxytrityl)-6-thioinosine (23) was synthesized via substitution of the 5'-O-tritylated 6-chloropurine riboside derivative 22 with 2-cyanoethanethiol. These S-(2-cyanoethyl)thionucleosides were converted to the 2'-O-(tert-butyldimethylsilyl)ribonucleoside 3'-phosphoramidite derivatives 7, 18, and 26 or 3',5'-bisphosphate derivatives 8, 19, and 27. Treatment of 8, 19, and 27 with DBU gave thionucleoside 3',5'-bisphosphate derivatives 9, 20, and 28, which were found to be substrates of T4 RNA ligase. These thionucleoside 3',5'-bisphosphates were examined as donors for ligation with m3(2,2,7) G5'pppAmUmA, i.e., the 5'-terminal tetranucleotide fragment of U1 snRNA, The 4-thiouridine 3',5'-bisphosphate derivative 9 was found to serve as the most active substrate of T4 RNA ligase with a reaction efficiency of 96%.     

Dichloro organosilicon bismuthanes as precursors for rare compounds with a bismuth-pnictogen or bismuth-tellurium bond

The chloro-bridged interpnictogen compounds [tBu?PhSiE{BiClCH(SiMe?)?}?] (E = P (4), As (5)) can be synthesized by the reaction of [tBu?PhSiELi?] (E = P (2), As (3)) with (Me?Si)?CHBiCl? in a molar ratio of 1?:?2. The reaction of iPr?SiAs(SiMe?)? with (Me?Si)?CHBiCl? yields the analogous compound [iPr?SiAs{BiClCH(SiMe?)?}?] (6) as well as the diarsine species [As{BiClCH(SiMe?)?}?]? (7). Preparation of 7 is also possible in the reaction of As(SiMe?)? with (Me?Si)?CHBiCl?. Starting from (Me?Si)?SiTeSiMe?, the Bi/Te compounds [{(Me?Si)?SiTe}?BiR] (R = CH(SiMe?)? (8), C(SiMe?)? (9)) are obtained by the reaction with RBiCl? (R = CH(SiMe?)?, C(SiMe?)? (1)). The intermediate and final products are characterized by multinuclear NMR spectroscopy and IR spectroscopy. Furthermore, crystal structures determined by X-ray diffraction are described for compounds 1 and 3-9.     

Highly efficient alkene epoxidation and aziridination catalyzed by iron(II) salt + 4,4',4'-trichloro-2,2':6',2'-terpyridine/4,4'-dichloro-4'-O-PEG-OCH3-2,2':6',2'-terpyridine

"Iron(II) salt + 4,4',4'-trichloro-2,2':6',2'-terpyridine" is an effective catalyst for epoxidation and aziridination of alkenes and intramolecular amidation of sulfamate esters. The epoxidation of allylic-substituted cycloalkenes achieved excellent diastereoselectivities up to 90%. ESI-MS results supported the formation of iron-oxo and -imido intermediates. Derivitization of Cl 3terpy to O-PEG-OCH 3-Cl 2terpy renders the terpyridine unit to be recyclable, and the "iron(II) salt + 4,4'-dichloro-4'- O-PEG-OCH 3-2,2':6',2'-terpyridine" protocol can be reused without a significant loss of catalytic activity in the alkene epoxidation.